Clinical characteristics and outcomes in pulmonary manifestations of systemic sclerosis: Contribution from pulmonary hypertension and interstitial lung disease severity is a research paper published in Pulmonary Circulation (2022). On theSindex it has a DataRank of 0. It has been cited 12 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Health Resources and Services Administration
Grant: U1EMC27864‐08‐00
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: CCCR P30 AR072571
National Center for Advancing Translational Sciences
Grant: 2UL1TR001430‐05A1
National Heart, Lung, and Blood Institute
Grant: 1F32HL156614‐01
National Heart, Lung, and Blood Institute
Grant: 1UG3HL143192‐01A1
National Heart, Lung, and Blood Institute
Grant: 5F32HL149236‐02
NIAMS NIH HHS
Grant: P30 AR072571
NCATS NIH HHS
Grant: UL1 TR001430
NHLBI NIH HHS
Grant: UG3 HL143192
NHLBI NIH HHS
Grant: F32 HL149236
NHLBI NIH HHS
Grant: F32 HL156614
National Institutes of Health
Grant: 5F32HL149236-02
Determining disparities in treatment of pulmonary arterial hypertension nationally
National Institutes of Health
Grant: 1UG3HL143192-01A1
1/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
National Institutes of Health
Grant: 3UL1TR001430-05A1S2
Boston University Clinical and Translational Science Institute
National Institutes of Health
Grant: 1F32HL156614-01
Left Ventricular Strain in Systemic Sclerosis-related Pulmonary Hypertension
National Institutes of Health
Grant: 1P30AR072571-01A1
Boston University CCCR
Bayer
Novartis
Rheumatology Research Foundation
FWCI
1.63
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals